Currently Viewing:
Evidence-Based Diabetes Management May 2014

Stem Cells Create a Therapeutic Niche

Surabhi Dangi-Garimella, PhD
Stem cell therapy has gained increasing traction in various therapeutic areas, from diabetes to cancer to ocular regeneration. Although the use of embryonic stem cells is controversial, remarkable research in the field of adult induced pluripotent stem cells (iPSCs) has highlighted the tremendous potential of this unique treatment in development and regeneration. Additionally, understanding how stem cells function would improve our insight into various diseases—to fathom “what went wrong.”

Globally, patients are actively being recruited to participate in clinical trials of these regenerative therapies. A biotechnology company, Advanced Cell Technology, is testing human embryonic stem cell (hESC)-derived retinal cells for 2 different eye diseases: Stargardt’s macular dystrophy,1 which is a form of juvenile macular degeneration, and age-related macular degeneration. 2 These are primarily phase 1 and 2 safety and efficacy trials, and a preliminary report published in early 2012 did not observe any safety issues with the therapy.3 Hematopoietic stem cells (HSCs), isolated from the bone marrow or umbilical cord blood, have been widely used to treat blood cancers and other blood disorders for a while now. Osiris Therapeutics, based out of Columbia, Maryland, is currently conducting phase 2 trials using human mesenchymal stem cells (MSCs) to repair heart tissue following a heart attack, repair lung tissue in chronic obstructive pulmonary disease patients, and protect pancreatic beta cells in patients with newly diagnosed type 1 diabetes mellitus (T1DM).4

Researchers at the Joslin Diabetes Center, an affiliate of Harvard Medical School, believe that stem cells have tremendous potential for treating many diseases, including T1DM and type 2 diabetes mellitus (T2DM). The current research at the institute is geared toward generating insulin-producing stem cells for islet transplant and regenerative medicine to repair tissue damage associated with long-term diabetes.5

While bone marrow transplants for numerous blood disorders, including cancer, have been covered by insurance policies for some time now, stem cell therapies are increasingly gaining attention with improved and less ethically challenging procedures being developed from adult stem cells.

The Basics

Stem cells, during early stages of development (in infants and children), have the unique potential to develop into any cell type, a property defined as “pluripotency.” Additionally, stem cells, even in adults, have “regenerative” potential, which helps them replenish damaged tissues and organs. These cells present distinct behavior depending on their site or location in the body, and they respond to specific environmental cues. For example, stem cells in the gut and HSCs regularly divide to repair and replenish worn-out tissues, while stem cells in organs like the pancreas or the heart divide only under specific conditions.

Distinct from other cell types, stem cells have the ability to undergo cell division and replicate, even after dormancy. Additionally, following specific cues, they can be prompted to differentiate into tissue- or organ-specific cells with special functions.6 Although every human organ (except nerve cells) can undergo repair by stem cells, the process dwindles with age, or is quite inactive in some organs and tissues.7 Most of the current research, independent of the therapeutic area, is geared toward understanding the stimuli that activate/ reactivate stem cells to allow for age- or disease-related tissue damage.

Types of Stem Cells

The human body is primarily the source of 2 types of stem cells: embryonic stem cells and adult or somatic stem cells. hESCs are derived from embryos that remain unused following in vitro fertilization, following the informed consent of the donor.6 These cells need specific signals to differentiate to the required cell type, but they run the risk of developing into a tumor if injected directly.Thus, in addition to the associated ethical issues, tumor formation and transplant rejection are some of the barriers faced with hESCs.9

The use of adult stem cells, such as HSCs, does not involve any ethical issues, and when obtained from the recipient, the cells are not susceptible to immune rejection. An adult stem cell—an undifferentiated cell that exists among differentiated cells in a tissue or organ—is capable of generating the cell types of the tissue in which it resides, and maybe unipotent or multipotent. The field is burgeoning, and there is tremendous excitement among researchers to use adult stem cells in therapy. While HSCs have long been used in stem cell transplants, MSCs (non-HSCs) can generate cartilage, bone, and fat cells to form blood and fibrous connective tissue (Figure 1).6

Exciting, albeit controversial, results of human cloning were recently published in the journal Cell Stem Cell following collaborative research conducted by scientists at the CHA Stem Cell Institute in Seoul, Korea, the Research Institute for Stem Cell Research (a part of the CHA Health Systems), and the company Advanced Cell Technology. The scientists “reprogrammed” an egg cell by removing its DNA and replacing it with nuclei from 2 adult donors aged 35 years and 75 years. The experimental procedures could successfully generate 2 karyotypically normal diploid ESC lines. This technique had previously been developed, but with infant/fetal donor cells, which, unlike adult cells, are not associated with age-related changes such as shortened telomerases and oxidative DNA damage.10

A company called ViaCyte, which partners with Johnson & Johnson Development Corporation among others and is funded by the California Institute of Regenerative Medicine, has developed an implantable device by fusing stem cell engineering with biotechnology. The company has developed a patented process to reproducibly differencells, using specific types and amounts of growth factors, growth media, and supplements.11 Following subcutaneous implantation in individuals with diabetes, the cells are expected to mature into functional beta cells, a technique that proved promising in an animal model.12 The company hopes to initiate phase 1/2a trials this year and also file for an investigational new drug application.


Extracting and then maintaining adult stem cells in the laboratory is extremely difficult, as they have a limited capacity to divide in culture.6 The discovery of the “transdifferentiation” process of adult stem cells, wherein adult stem cells are subjected to certain differentiation techniques to generate cell types different from the predicted types, was therefore very exciting.9 Taking the process a step further, researchers in Japan developed a technique to reprogram normal adult cells into stem cells, called iPSCs, by the forced introduction of a set of transcription factors into the cells.13 These transcription factors (different combinations of Oct4, Sox2, Klf4, c-Myc, Nanog, Lin28) regulate important steps in early embryonic development and force the adult somatic cells into an embryonic stem cell–like state. This technique has essentially revolutionized the field of regenerative medicine; the patient himself could now be an unlimited source of immune-matched pluripotent cells.14

As promising as the therapy sounds, it is riddled with its own problems. It has always been known that the genes that regulate developmental pathways also regulate cancer, and are especially potent when expressed in combination. Therefore, researchers have trimmed the initial group of 4 transcription factors down to 2, with the aim of simultaneously treating the cells with various chemicals to boost reprograming efficiency. Additionally, the use of either lentiviruses or retroviruses (Figure 2) to introduce the genes into the host cell can result in uncontrolled effects of viral integration. Current efforts are directed toward reprograming cells without viruses or using more efficient integration techniques.14

Applications of iPSCs

iPSCs offer tremendous potential in understanding disease, developing drug candidates, and regenerative medicine. Disease-specific iPSCs are being developed to treat Alzheimer’s disease, Parkinson’s disease, cardiovascular disease, diabetes, and ALS/ Lou Gehrig’s disease.14 Researchers at the RIKEN Center for Developmental Biology in Japan have piloted the first set of studies to evaluate iPSCs in humans. In August 2013, patient recruitment was initiated to evaluate the safety and efficacy of iPSC-derived retinal pigment epithelium (RPE) cells in patients with age-related macular degeneration.15 The premise for using iPSCs is the fact that the current remedies for the disease prevent further damage without promoting any repair.

A new iPSC transplantation therapy will also be evaluated for safety in patients with Parkinson’s disease. Jun Takahashi, MD, PhD, and his colleagues at the Kyoto University’s Center for iPS Cell Research and Application have successfully developed a technique to generate dopamine-producing nerve cells from patient-derived iPSCs for transplantation into the patient’s brain, an attempt at regenerating the damaged dopaminergic neurons.16 When contacted by e-mail, Takahashi responded that they are currently conducting preclinical studies, the results from which will be submitted for approval prior to initiating clinical trials.

In an encouraging development on the diabetes front, Rohit Kulkarni, MD, PhD, and his team at Joslin reported the generation of human iPSCs (hiPSCs) from patients suffering from maturity onset diabetes of the young (MODY). MODY accounts for 1% to 5% of diabetics in the United States and is monogenic (mutation of a single gene), unlike T1DM and T2DM, which are polygenic and are influenced by genetic and environmental factors. By stimulating the MODY-hiPSCs to differentiate into beta cells, the research team plans to evaluate potential blocks in the process, as well as explore means to correct the genetic defect with the objective of developing personalized disease treatments.17

Healthcare Coverage

Is regenerative medicine covered? Payers such as Humana, Blue Cross and Blue Shield, Aetna, and UnitedHealthcare definitely have policies in place for HSC and bone marrow transplants, a procedure that has been in use for a long time now for patients with blood disorders. However, companies that have developed, or are in the process of developing, regenerative therapies, face hurdles with not just the FDA, but also reimbursement.

The company Advanced BioHealing developed Dermagraft, a product that consists of allogenic human fibroblasts, to aid with wound closures in diabetic foot ulcers. In 2011, the company was acquired by Shire Pharmaceuticals, which immediately initiated the task of improving the reimbursement profile for Dermagraft and put 2 new procedure codes in place for the product.18

Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up